KẾT QUẢ BƯỚC ĐẦU ĐIỀU TRỊ PHÁC ĐỒ R-CHOP U LYMPHO ÁC TÍNH KHÔNG HODGKIN TẾ BÀO B LỚN LAN TỎA TẠI BỆNH VIỆN ĐÀ NẴNG

Abstract

Objectives: To evaluate the initial results of R-CHOP regimen in diffuse large B-cell non-Hodgkin lymphoma. Patients and Methods: A retrospective combined with prospective descriptive study on 60 diffuse large B-cell lymphoma patients treated with R-CHOP regimen at the Department of Oncology, Da Nang Hospital, from January 2018 to April 2025. Results: The complete response rate after 3 cycles was 38.3%, and 76.7% after treatment completion. This rate was higher in patients under 60 years old compared to those over 60 years old (79.5% vs. 71.4%), in limited-stage (I-II) compared to advanced-stage (III-IV) (78.6% vs. 75%), and in patients with low- and intermediate-risk IPI (0-3 points) compared to those with high-risk IPI (4-5 points) (80.8% vs. 50%) but not statistically significant. Common clinical toxicities were alopecia (100%), nausea (45%), and oral mucositis (28.3%), mainly grade 1-2. Common hematological toxicities were anemia (78.3%) and neutropenia (70%, grade 3-4 31.7%). Conclusion: R-CHOP regimen is an effective and safe treatment with acceptable toxicity.